Eisai breast cancer drug obtains Japanese approval
Japanese approval was given on the basis a pivotal Phase III Embrace (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) study results and a Phase II
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.